RenovoRx Advances TIGeR-PaC Trial for Pancreatic Cancer with Novel TAMP Therapy
• RenovoRx's TIGeR-PaC Phase III trial evaluates TAMP therapy for locally advanced pancreatic cancer, aiming to improve survival and reduce side effects.
• SCRI Oncology Partners has initiated patient enrollment, expanding the trial's reach across a network of over 250 locations in the U.S.
• Pharmacokinetic data presented at ASCO GI 2025 supports TAMP's potential to enhance local drug potency while minimizing systemic exposure to gemcitabine.
• RenovoRx anticipates completing patient enrollment and the second interim analysis for the TIGeR-PaC trial by the first half of 2025.
© Copyright 2025. All Rights Reserved by MedPath